Fig. 4
From: Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma
HDACi modulate decitabine-induced RIG-1 and MDA5 expression in MPM cells. Meso96 (a, b), Meso34 (c, d), and Meso45 (e, f) cells were treated with: VPA 5 mM, SAHA 2.5 μM, ODB 7.5 μM, NODB 2.5 μM, ODH 2.5 μM, and NODH 25 nM (48 h) in combination or not with decitabine (5-aza) 500 nM (72 h pretreatment). RIG-1 (a, c, and e) and MDA5 (b, d, and f) mRNA expression were measured using real time PCR. *p < 0.05 and **p < 0.01